D.A. Davidson & CO. Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

D.A. Davidson & CO. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,421 shares of the medical research company’s stock after selling 5,455 shares during the period. D.A. Davidson & CO.’s holdings in IQVIA were worth $3,816,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IQV. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the 3rd quarter worth $27,000. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the 4th quarter worth $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new stake in IQVIA in the third quarter valued at $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 1.3 %

Shares of IQVIA stock opened at $194.01 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company’s 50-day simple moving average is $199.86 and its 200-day simple moving average is $216.95. The firm has a market cap of $34.16 billion, a price-to-earnings ratio of 25.87, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on IQV. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.